PFF Help Center(844) 825-5733

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

Drug

Seralutinib

Status:

Phase 3

Condition:

Pulmonary Hypertension ILD

Intervention Type:

Inhaled Drug

Funder Type:

Industry

Drug Details

Seralutinib is an inhaled, investigational, small-molecule kinase inhibitor designed to treat pulmonary arterial hypertension (PAH).

Study Purpose

This drug has no clinical trials actively recruiting patients at this time.